IMPORTANCE: Orbital inflammation is a potentially blinding and disfiguring disease process that is often treated with systemic corticosteroids and immunosuppression; better treatments are needed. OBJECTIVE: To determine whether rituximab, a monoclonal antibody against the B-lymphocyte antigen CD20, is effective in the treatment of refractory orbital inflammation. DESIGN, SETTING, AND PARTICIPANTS: A dose-ranging, randomized, double-masked phase 1/2 clinical trial was conducted at a tertiary referral ophthalmology clinic. Ten individuals with orbital inflammation refractory to systemic corticosteroids and at least 1 other immunosuppressive agent were enrolled from January 2007 to March 2010. INTERVENTIONS:Rituximab infusions were administered on study days 1 and 15 at doses of either 500 mg or 1000 mg. Initial responders with recurrent inflammation after week 24 were permitted reinfusion with an additional cycle of 2 open-label 1000-mg rituximab infusions. MAIN OUTCOMES AND MEASURES: The primary outcomes were reduction of inflammation measured with a validated orbital disease grading scale and corticosteroid dose reduction by at least 50%. The secondary outcomes were visual acuity, reduction in pain, and participant- and physician-reported global health assessment. RESULTS: Of 10 enrolled patients, 7 demonstrated improvement on the orbital disease grading scale at the 24-week end point with rituximab therapy. Of these 7 individuals, 4 were receiving corticosteroids at study inception and all achieved successful dose reduction. For the secondary outcome measures in the 10 participants, 7 patients and 8 patients improved in self-rated and physician global health scores, respectively, and 7 patients had reduction in pain by 25% or more at 24 weeks. Four patients who were positive responders at the week 24 end point experienced breakthrough inflammation after week 24 and received reinfusions between 24 and 48 weeks. Vision remained stable in all participants. Three of 10 patients had short-term objective or subjective worsening 2 to 8 weeks after receiving rituximab infusions, which was averted in subsequent patients with oral corticosteroids administered during the infusion and did not affect the eventual positive treatment outcome. No significant differences with regard to efficacy, toxicity, or likelihood of retreatment were noted between the dosing arms. CONCLUSIONS AND RELEVANCE: Rituximab was safe and effective in 7 of 10 patients with noninfectious orbital disease, although 4 required reinfusion with rituximab to maintain control of orbital inflammation. Substantial toxicity was not noted. Rituximab should be considered in the treatment of refractory orbital inflammation. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00415506.
RCT Entities:
IMPORTANCE: Orbital inflammation is a potentially blinding and disfiguring disease process that is often treated with systemic corticosteroids and immunosuppression; better treatments are needed. OBJECTIVE: To determine whether rituximab, a monoclonal antibody against the B-lymphocyte antigen CD20, is effective in the treatment of refractory orbital inflammation. DESIGN, SETTING, AND PARTICIPANTS: A dose-ranging, randomized, double-masked phase 1/2 clinical trial was conducted at a tertiary referral ophthalmology clinic. Ten individuals with orbital inflammation refractory to systemic corticosteroids and at least 1 other immunosuppressive agent were enrolled from January 2007 to March 2010. INTERVENTIONS:Rituximab infusions were administered on study days 1 and 15 at doses of either 500 mg or 1000 mg. Initial responders with recurrent inflammation after week 24 were permitted reinfusion with an additional cycle of 2 open-label 1000-mg rituximab infusions. MAIN OUTCOMES AND MEASURES: The primary outcomes were reduction of inflammation measured with a validated orbital disease grading scale and corticosteroid dose reduction by at least 50%. The secondary outcomes were visual acuity, reduction in pain, and participant- and physician-reported global health assessment. RESULTS: Of 10 enrolled patients, 7 demonstrated improvement on the orbital disease grading scale at the 24-week end point with rituximab therapy. Of these 7 individuals, 4 were receiving corticosteroids at study inception and all achieved successful dose reduction. For the secondary outcome measures in the 10 participants, 7 patients and 8 patients improved in self-rated and physician global health scores, respectively, and 7 patients had reduction in pain by 25% or more at 24 weeks. Four patients who were positive responders at the week 24 end point experienced breakthrough inflammation after week 24 and received reinfusions between 24 and 48 weeks. Vision remained stable in all participants. Three of 10 patients had short-term objective or subjective worsening 2 to 8 weeks after receiving rituximab infusions, which was averted in subsequent patients with oral corticosteroids administered during the infusion and did not affect the eventual positive treatment outcome. No significant differences with regard to efficacy, toxicity, or likelihood of retreatment were noted between the dosing arms. CONCLUSIONS AND RELEVANCE: Rituximab was safe and effective in 7 of 10 patients with noninfectious orbital disease, although 4 required reinfusion with rituximab to maintain control of orbital inflammation. Substantial toxicity was not noted. Rituximab should be considered in the treatment of refractory orbital inflammation. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00415506.
Authors: Rachel B Jones; Jan Willem Cohen Tervaert; Thomas Hauser; Raashid Luqmani; Matthew D Morgan; Chen Au Peh; Caroline O Savage; Mårten Segelmark; Vladimir Tesar; Pieter van Paassen; Dorothy Walsh; Michael Walsh; Kerstin Westman; David R W Jayne Journal: N Engl J Med Date: 2010-07-15 Impact factor: 91.245
Authors: Christopher I Zoumalan; Kimberly P Cockerham; Roger E Turbin; Nicholas J Volpe; Michael Kazim; Raymond S Douglas; Steven E Feldon Journal: J Neuroophthalmol Date: 2007-09 Impact factor: 3.042
Authors: Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw Journal: N Engl J Med Date: 2004-06-17 Impact factor: 91.245
Authors: Philip J Mease; Dennis A Revicki; Jacek Szechinski; Maria Greenwald; Alan Kivitz; Leonor Barile-Fabris; Jatinderpal Kalsi; Jennifer Eames; Marjatta Leirisalo-Repo Journal: J Rheumatol Date: 2007-11-15 Impact factor: 4.666
Authors: Ronald F van Vollenhoven; Paul Emery; Clifton O Bingham; Edward C Keystone; Roy M Fleischmann; Daniel E Furst; Nicola Tyson; Neil Collinson; Patricia B Lehane Journal: Ann Rheum Dis Date: 2012-11-07 Impact factor: 19.103
Authors: Tania Sales de Alencar de Fidelix; Luis Antonio Vieira; Denise de Freitas; Virginia Fernandes Moça Trevisani Journal: Int Ophthalmol Date: 2015-08-29 Impact factor: 2.031
Authors: James T Rosenbaum; Dongseok Choi; David J Wilson; Hans E Grossniklaus; Christina A Harrington; Cailin H Sibley; Roger A Dailey; John D Ng; Eric A Steele; Craig N Czyz; Jill A Foster; David Tse; Chris Alabiad; Sander Dubovy; Prashant K Parekh; Gerald J Harris; Michael Kazim; Payal J Patel; Valerie A White; Peter J Dolman; Bobby S Korn; Don O Kikkawa; Deepak P Edward; Hind M Alkatan; Hailah al-Hussain; R Patrick Yeatts; Dinesh Selva; Patrick Stauffer; Stephen R Planck Journal: Exp Mol Pathol Date: 2015-07-08 Impact factor: 3.362
Authors: James T Rosenbaum; Cailin H Sibley; Dongseok Choi; Christina A Harrington; Stephen R Planck Journal: Prog Retin Eye Res Date: 2015-12-01 Impact factor: 21.198
Authors: Timothy E Ortlip; Virginia E Drake; Prashant Raghavan; John C Papadimitriou; Neil C Porter; David J Eisenman; Ronna Hertzano Journal: Otol Neurotol Date: 2017-08 Impact factor: 2.311
Authors: Faruque Ghanchi; Rupert Bourne; Susan M Downes; Richard Gale; Christina Rennie; Ian Tapply; Sobha Sivaprasad Journal: Eye (Lond) Date: 2022-01-01 Impact factor: 4.456